First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness
Introduction to First-Generation and Second-Generation Antipsychotics (2 of 4)
First-generation antipsychotics (FGAs) are associated with side effects that are difficult to manage and, in some cases, are irreversible. Examples of the more difficult side effects are extrapyramidal symptoms and tardive dyskinesia. Second-generation antipsychotics (SGAs) were developed in response to a desire to avoid these adverse effects. SGAs are not as strongly associated with neuromotor side effects as the FGAs. However, they are associated with elevated risks for dyslipidemia, weight gain, metabolic syndrome, and diabetes mellitus.
Keywords: antipsychotics | first-generation antipsychotics | second-generation antipsychotics | typical antipsychotics | atypical antipsychotics | adverse effects | neuromotor side effects | extrapyramidal symptoms | tardive dyskinesia | dyslipidemia | weight gain | metabolic syndrome | diabetes mellitus
- Abou-Setta AM, Mousavi SS, Spooner C, et al. First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness. Comparative Effectiveness Review No. 63 (Prepared by the University of Alberta Evidence-based Practice Center under Contract No. 290-2007-10021). Rockville, MD: Agency for Healthcare Research and Quality; August 2012. AHRQ Publication No. 12-EHC054-EF. Available at www.effectivehealthcare.ahrq.gov/antipsychotics-adult.cfm.
Your slide tray is being processed.